Browse FADS2

Summary
SymbolFADS2
Namefatty acid desaturase 2
Aliases FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ......
Chromosomal Location11q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Multi-pass membrane protein
Domain PF00173 Cytochrome b5-like Heme/Steroid binding domain
PF00487 Fatty acid desaturase
Function

Component of a lipid metabolic pathway that catalyzes biosynthesis of highly unsaturated fatty acids (HUFA) from precursor essential polyunsaturated fatty acids (PUFA) linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3). Catalyzes the first and rate limiting step in this pathway which is the desaturation of LA (18:2n-6) and ALA (18:3n-3) into gamma-linoleic acid (GLA) (18:3n-6) and stearidonic acid (18:4n-3) respectively and other desaturation steps. Highly unsaturated fatty acids (HUFA) play pivotal roles in many biological functions. It catalizes as well the introduction of a cis double bond in palmitate to produce the mono-unsaturated fatty acid sapienate, the most abundant fatty acid in sebum.

> Gene Ontology
 
Biological Process GO:0001676 long-chain fatty acid metabolic process
GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006636 unsaturated fatty acid biosynthetic process
GO:0016053 organic acid biosynthetic process
GO:0033559 unsaturated fatty acid metabolic process
GO:0036109 alpha-linolenic acid metabolic process
GO:0043651 linoleic acid metabolic process
GO:0044283 small molecule biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0072330 monocarboxylic acid biosynthetic process
Molecular Function GO:0004768 stearoyl-CoA 9-desaturase activity
GO:0016213 linoleoyl-CoA desaturase activity
GO:0016215 acyl-CoA desaturase activity
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0016717 oxidoreductase activity, acting on paired donors, with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa03320 PPAR signaling pathway
hsa00592 alpha-Linolenic acid metabolism
hsa01040 Biosynthesis of unsaturated fatty acids
hsa01212 Fatty acid metabolism
Reactome R-HSA-2046105: Linoleic acid (LA) metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-2046104: alpha-linolenic (omega3) and linoleic (omega6) acid metabolism
R-HSA-2046106: alpha-linolenic acid (ALA) metabolism
Summary
SymbolFADS2
Namefatty acid desaturase 2
Aliases FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ......
Chromosomal Location11q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FADS2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFADS2
Namefatty acid desaturase 2
Aliases FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ......
Chromosomal Location11q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FADS2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFADS2
Namefatty acid desaturase 2
Aliases FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ......
Chromosomal Location11q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FADS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5250.298
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7180.726
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3770.796
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9910.029
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2180.513
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6980.781
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0970.842
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0060.997
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1260.935
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6770.727
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1150.7
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.120.498
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FADS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFADS2
Namefatty acid desaturase 2
Aliases FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ......
Chromosomal Location11q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FADS2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFADS2
Namefatty acid desaturase 2
Aliases FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ......
Chromosomal Location11q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FADS2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FADS2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFADS2
Namefatty acid desaturase 2
Aliases FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ......
Chromosomal Location11q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FADS2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFADS2
Namefatty acid desaturase 2
Aliases FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ......
Chromosomal Location11q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FADS2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFADS2
Namefatty acid desaturase 2
Aliases FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ......
Chromosomal Location11q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FADS2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFADS2
Namefatty acid desaturase 2
Aliases FADSD6; D6D; TU13; DES6; SLL0262; delta-6-desaturase; LLCDL2; delta(6) desaturase; delta(6) fatty acid desat ......
Chromosomal Location11q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FADS2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FADS2.
ID Name Drug Type Targets #Targets
DB00132Alpha-Linolenic AcidSmall MoleculeELOVL4, FADS1, FADS2, NR1H4, PPARA, PPARD, PPARG, RXRA, SLC8A1, TR ......10